<DOC>
	<DOCNO>NCT02722642</DOCNO>
	<brief_summary>Bronchiectasis result chronic inflammation compound inability clear mucoid secretion . Inflammation result progressive destruction normal lung architecture , particular elastic fiber bronchi . Currently effective drug bronchiectasis . This study intend carry open , single-center , non-randomized , self control phase I/II clinical trial . During treatment , bronchial basal cell ( BCCs ) isolate patient ' bronchus bronchoscopic brush expand vitro . Cultured cell inject directly lesion fiberoptic bronchoscopy lavage . After six-month observation , investigator evaluate safety effectiveness treatment measure key indicator -- CT imaging dilate bronchi well four secondary indicator include pulmonary function , laboratory factor level , incidence acute exacerbation patient ' self-evaluation .</brief_summary>
	<brief_title>Autologous Bronchial Basal Cells Transplantation Treatment Bronchiectasis</brief_title>
	<detailed_description>Bronchiectasis term irreversible lung damage result recurrent episode infection inflammation . Bronchial basal cell ( BCCs ) proven stem cell activity regenerate bronchus repair lung damage . In single-center , non-randomized , self control phase I/II clinical trial , patient ' BCCs grown laboratory inject damage part lung tissue . Transplanted BCCs potential replenish bronchial epithelium reconstruct respiratory architecture .</detailed_description>
	<mesh_term>Bronchiectasis</mesh_term>
	<criteria>Subjects diagnose bronchiectasis . Subjects least 6 lung segment affect . Subjects stable condition 2 week . Subjects tolerate bronchoscopy . Subjects sign informed consent . Women childbearing age stage pregnancy lactation , without take effective contraceptive measure . Subjects syphilis HIV positive antibody . Subjects malignancy . Subjects suffer follow pulmonary disease : active tuberculosis , pulmonary embolism , pneumothorax , multiple huge bulla , uncontrolled asthma , acute exacerbation chronic bronchitis extremely severe COPD . Subjects suffer serious disease , diabetes , myocardial infarction , unstable angina , cirrhosis , acute glomerulonephritis . Subjects leukopenia ( WBC le 4x10^9 / L ) agranulocytosis ( WBC le 1.5x10^9 / L neutrophils less 0.5x10^9 / L ) cause reason . Subjects severe renal impairment , serum creatinine &gt; 1.5 time upper limit normal . Subjects liver disease liver damage : ALT , AST , total bilirubin &gt; 2 time upper limit normal . Subjects history mental illness suicide risk , history epilepsy central nervous system disorder . Subjects severe arrhythmia ( ventricular tachycardia , frequent superventricular tachycardia , atrial fibrillation , atrial flutter , etc . ) cardiac degree II conduction abnormality display via 12lead ECG . Subjects history alcohol illicit drug abuse . Subjects accept clinical trial within 3 month enrollment . Subjects poor compliance , difficult complete study . Any condition might increase risk subject interfere clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>